Search results for " Suppressor"

showing 10 items of 462 documents

Havep53 gene mutations and protein expression a different biological significance in colorectal cancer?

2002

p53 alterations are considered the most common genetic events in many types of neoplasms, including colorectal carcinoma (CRC). These alterations include mutations of the gene and/or overexpression of the protein. The aim of our study was to assess whether in 160 patients undergoing resective surgery for primary operable CRC there was an association between p53 mutations and protein over-expression and between these and other biological variables, such as cell DNA content (DNA-ploidy) and S-phase fraction (SPF), and the traditional clinicopathological variables. p53 mutations, identified by PCR-SSCP-sequencing analysis, were found in 68/160 patients (43%) and positive staining for p53 prote…

AdultAged 80 and overMaleBase SequenceDNA Mutational AnalysisP53 colorectal cancerDNAMiddle AgedGenes p53ImmunohistochemistryProtein Structure TertiaryGene Expression Regulation NeoplasticMutationHumansFemaleGenetic TestingProspective StudiesIntestinal MucosaTumor Suppressor Protein p53Colorectal NeoplasmsAged
researchProduct

MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients

2010

A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and CDKN1A (p21/Waf1/Cip1) codon 31 (rs1801270) polymorphisms in 86 cases of cutaneous Kaposi's sarcoma (KS) from African and Caucasian patients, and 210 healthy controls. A significant increase of the MDM2 SNP309 T/G genotype was observed among classic KS cases (odds ratio 2.38, 95% confidence interval 1.0-5.5). Frequencies of CDKN1A codon 31 genotypes were not significantly different between cases and controls. The results suggest that the MDM2 SNP309 G allele may act as a susceptibility gene fo…

AdultCyclin-Dependent Kinase Inhibitor p21MaleGenotypeHealth Toxicology and MutagenesisClinical BiochemistryBlack PeopleBiologyPolymorphism Single NucleotideBiochemistryWhite PeopleYoung AdultGene FrequencyRisk FactorsGenotypemedicineHumansGenetic Predisposition to DiseaseAlleleYoung adultSarcoma KaposiKaposi's sarcomaAllele frequencyAgedAged 80 and overProto-Oncogene Proteins c-mdm2Odds ratioMiddle Agedmedicine.diseaseConfidence intervalImmunologyCancer researchFemaleSarcomaTumor Suppressor Protein p53
researchProduct

Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors.

2001

The EWS-ETS rearrangements, and their respective fusion gene products, are specifically associated with histopathologically Ewing family tumors (EFT). These translocations are implicated in generating malignant transformation of EFT, but the presence of additional genetic alterations must be considered in the pathogenesis of such tumors. We analyzed 26 samples (biopsies and/or nude mice xenotransplants) collected from 19 patients with an EFT to determine whether molecular and cytogenetic alterations of the G(1)/S checkpoint genes are implicated in the pathogenesis of EFT. We found inactivating p53 mutations in three (16%) cases, which correlated with a loss of p21(WAF1/Cip1) expression and …

AdultCyclin-Dependent Kinase Inhibitor p21MaleMonosomyTumor suppressor geneAdolescentTransplantation HeterologousGene ExpressionChromosome 9Locus (genetics)Sarcoma EwingBiologymedicine.disease_causePathology and Forensic MedicineFusion geneMiceCyclinsProto-Oncogene ProteinsmedicineAnimalsHumansPoint MutationCyclin D1ChildMolecular BiologyGeneGene AmplificationChromosome MappingCyclin-Dependent Kinase 4Nuclear ProteinsProto-Oncogene Proteins c-mdm2Cell BiologyDNA Methylationmedicine.diseaseGenes p53Survival AnalysisCyclin-Dependent KinasesChromosome 17 (human)Child PreschoolCancer researchFemaleCarcinogenesisChromosomes Human Pair 9Gene DeletionNeoplasm TransplantationLaboratory investigation; a journal of technical methods and pathology
researchProduct

Upregulation of the netrin receptor (DCC) gene during activation of b lymphocytes and modulation by interleukins.

2001

The DCC (deleted in colon cancer) gene has a brain restricted high expression pattern. It encodes a transmembrane protein of the immunoglobulin superfamily identified as the netrin-1 receptor. It might be a member of the so called "brain-lymphoid" molecules, which control key cell surface events. To test this hypothesis we have assessed the DCC mRNA level in human normal and malignant myeloid and lymphoid cells. A high mRNA content has been observed only in mature B cells at the secreting or presecreting stage. Expression of DCC was also assessed in the anti-CD40 model of immunopoiesis. Activation of purified tonsillar B cells by anti-CD 40 antibody strongly increased the DCC mRNA level and…

AdultDeleted in Colorectal CancerTranscription GeneticT-LymphocytesPalatine TonsilBiophysicsReceptors Cell SurfaceBiologyLymphocyte ActivationBiochemistryCell LineNetrin Receptor DCCDownregulation and upregulationNetrinmedicineTumor Cells CulturedHumansRNA MessengerReceptorMolecular BiologyB cellB-LymphocytesReverse Transcriptase Polymerase Chain ReactionInterleukinsTumor Suppressor ProteinsfungiBrainCell BiologyDCC ReceptorMolecular biologyInterleukin-10Up-Regulationmedicine.anatomical_structureGenes DCCCell cultureImmunoglobulin superfamilyInterleukin-2Netrin ReceptorsCell Adhesion MoleculesImmunologic MemoryMuromonab-CD3Biochemical and biophysical research communications
researchProduct

Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial …

2019

Hepatocellular carcinoma (HCC) is one of the most common human malignancies, the incidence of which is growing worldwide. The prognosis of HCC is very poor and it is often accompanied by a high rate of recurrence. Conventional chemotherapeutic approaches are largely inefficient. In order to develop novel effective methods for the early detection and prognosis of HCC, novel markers and therapeutic targets are urgently required. The present study focused on the effects of the expression of the tumor suppressor gene insulin‑like growth factor‑2 receptor (IGF2R) on patient survival and tumor recurrence in patients with HCC; this study paid specific attention to the influence of transarterial ch…

AdultLiver CirrhosisMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisTumor suppressor geneKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free SurvivalReceptor IGF Type 203 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaHumansGenetic Predisposition to DiseaseChemoembolization TherapeuticAgedAged 80 and overOncogenebusiness.industryLiver NeoplasmsCase-control studyCancerGeneral MedicineMiddle AgedPrognosismedicine.diseaseMolecular medicinedigestive system diseases030104 developmental biologyOncologyCase-Control Studies030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesOncology Reports
researchProduct

Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur

2019

Meningiomas are the most frequent primary brain tumor. Usually, they are curable by surgery, but even after seemingly complete resection, some low-grade lesions recur. Despite recent improvements, signatures having prognostic value in grade I tumors remain poorly characterized. The frequency and delicate location of these tumors suggest that the risk of recurrence might be more accurately predicted. Herein, we show an easy way to evaluate the methylation status of meningiomas and its correlation with the prognosis of the disease. A series of 120 meningiomas, including primary tumors and recurrences, were analyzed histopathologically, and 24 tumor suppressor genes (TSGs) were studied by meth…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyAdolescentBrain tumorDiseaseMLH1Epigenesis GeneticPathology and Forensic MedicineMeningiomaYoung Adult03 medical and health sciences0302 clinical medicineCDKN2BInternal medicineMeningeal NeoplasmsmedicineHumansGenes Tumor SuppressorClinical significanceChildAgedAged 80 and overbusiness.industryDNA MethylationMiddle Agedmedicine.disease030104 developmental biology030220 oncology & carcinogenesisBenign MeningiomaDNA methylationFemaleNeoplasm Recurrence LocalMeningiomabusinessHuman Pathology
researchProduct

Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases.

2008

BACKGROUND. Patients with small papillary thyroid carcinoma (PTC) may have a high incidence of regional lymph-node (LN) metastases at presentation, and these are considered to be an independent risk factor for tumor recurrence. A mutated transketolase transcript (TKTL1) has been found up-regulated in different human malignancies, and strong TKTL1 protein expression has been associated with aggressiveness and poor patient survival in several epithelial cancers. METHODS. TKTL1 protein expression was analyzed in 256 consecutive cases of PTCs ≤1.5 cm by immunohistochemistry with a specific anti-TKTL1 antibody. RNA analysis was performed by real-time polymerase chain reaction (PCR) in all cases …

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAdolescentTumor suppressor geneGene ExpressionSettore MED/08 - Anatomia PatologicaThyroid carcinomamedicineHumansThyroid NeoplasmsRisk factorLymph nodeAgedpapillary thyroid carcinoma (PTC) lymph-node (LN) metastases transketolase protein (TKTL1) tumor recurrence.biologybusiness.industryIncidence (epidemiology)CancerMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma Papillarymedicine.anatomical_structureOncologyLymphatic MetastasisDisease Progressionbiology.proteinCancer researchImmunohistochemistryFemaleTransketolaseAntibodybusiness
researchProduct

Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma.

2010

Promoter hypermethylation of tumor suppressor genes is a common feature of primary cancer cells. However, at date the somatic epigenetic events that occur in head and neck squamous cell carcinoma (HNSCC) tumorigenesis are not yet been well defined. In the present study we analysed the methylation status of the gene hypermethylated in cancer-1 (hic1), a gene located on chromosome 17p13.3, a region frequently lost in HNSCC. We analysed 22 HNSCC samples and three cell lines using methylation specific PCR (MSP). We found hic1 methylated in 21 out of 22 samples and in all three cell lines. Treatment of the cell lines with the demethylating agent 5-Azacytidin (5-Aza) resulted in the demethylation…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAntimetabolites AntineoplasticTumor suppressor geneBisulfite sequencingKruppel-Like Transcription FactorsBiologymedicine.disease_causechemistry.chemical_compoundCell Line TumormedicineHumansGenes Tumor SuppressorNeoplasm InvasivenessPromoter Regions GeneticneoplasmsAgedMethylationDNA MethylationMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaDemethylating agentGene Expression Regulation Neoplasticstomatognathic diseasesOncologychemistryEpidermoid carcinomaHead and Neck NeoplasmsCancer cellCancer researchAzacitidineCarcinoma Squamous CellFemaleOral SurgeryCarcinogenesisOral oncology
researchProduct

Loss of SMARCB1 expression in colon carcinoma

2020

International audience; SMARCB1 is a tumor suppressor gene, which is part of SWI/SNF complex involved in transcriptional regulation. Recently, loss of SMARCB1 expression has been reported in gastrointestinal carcinomas. Our purpose was to evaluate the incidence and prognostic value of SMARCB1 loss in colon carcinoma (CC). Patients with stage III CC (n = 1695), and a second cohort of 23 patients with poorly differentiated CC were analyzed. Immunohistochemistry for SMARCB1 was performed on tissue microarrays, and cases with loss of expression were controlled on whole sections. Loss of SMARCB1 was compared with the clinico-pathological and molecular characteristics, and the prognostic value wa…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyMedullary cavityTumor suppressor geneSMARCB1[SDV.CAN]Life Sciences [q-bio]/Cancercolon carcinomaYoung AdultGeneticsmedicineHumans0501 psychology and cognitive sciencesStage (cooking)SMARCB1AgedNeoplasm Staging0505 lawTissue microarrayBRAF V600Emismatch repair deficiencybusiness.industry05 social sciencesHistologySMARCB1 ProteinGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistry3. Good healthOncologyMedullary carcinomaColonic Neoplasms050501 criminologyImmunohistochemistryFemalebusiness050104 developmental & child psychologyCancer Biomarkers
researchProduct

Poorly differentiated synovial sarcoma: A case report

2001

Poorly differentiated synovial sarcoma is a rare soft tissue tumor. We studied a case arising in the pleural cavity of a young subject, characterised by the presence of spindle cell, small cell, and large epithelioid cell areas. We performed stains for mucosubstances and analysed the expression of cytokeratins 5/6, 7, 8, 18, 19, CEA, CD34, Ber-Ep4 and calretinin to characterize the phenotype of this neoplasm. We furthermore assessed immunohistochemically the presence of p53, Bcl-2, Bax and caspase 3, four apoptotic markers, to evaluate a relationship between apoptotic activity and the behaviour of this tumor. Our findings showed a strong presence of calretinin, p53 and Bcl-2 in all three ar…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPleural Neoplasms2734CD34Caspase 3Pathology and Forensic MedicineSynovial sarcomaImmunoenzyme TechniquesSarcoma SynovialS100 Calcium Binding Protein GBcl-2-associated X proteinCalretininProto-Oncogene ProteinsBiomarkers TumormedicineHumansCaspasebcl-2-Associated X ProteinbiologyCaspase 3ApoptosiSoft tissue tumorGeneral MedicinePoorly differentiated synovial sarcomamedicine.diseaseSynovial sarcomaNeoplasm ProteinsApoptosis; Calretinin; Poorly differentiated synovial sarcoma; Soft tissue tumors; Synovial sarcoma; Cancer Research; Oncology; 2734Proto-Oncogene Proteins c-bcl-2OncologyCalbindin 2Caspasesbiology.proteinSarcomaTumor Suppressor Protein p53CalretininEpithelioid cell
researchProduct